PGEN - Precigen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7200
-0.2500 (-8.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.9700
Open2.9700
Bid0.0000 x 900
Ask0.0000 x 2200
Day's Range2.6600 - 3.0500
52 Week Range1.2600 - 7.8000
Volume846,328
Avg. Volume1,321,646
Market Cap461.5M
Beta (5Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 06, 2020 - May 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Precigen Reports Fourth Quarter and Year End 2019 Financial Results
      PR Newswire

      Precigen Reports Fourth Quarter and Year End 2019 Financial Results

      Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced its fourth quarter financial results for 2019.

    • Precigen to Announce Fourth Quarter and Full Year 2019 Financial Results on March 2nd
      PR Newswire

      Precigen to Announce Fourth Quarter and Full Year 2019 Financial Results on March 2nd

      Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release fourth quarter and full year 2019 financial results after the market closes on Monday, March 2nd, 2020. The Company will host a conference call that day at 5:30 pm ET to discuss the results and provide a general business update.